Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com
Research analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock. Separately, Roth Capital cut shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, […]
1 Nov 06:02 · The Cerbat Gem